Senate Dems Push Full Cannabis Legalization as Trump Backs Rescheduling

Democratic senators have introduced comprehensive federal cannabis legalization legislation, setting up a stark policy contrast with the Trump administration's preference for rescheduling marijuana under the Controlled Substances Act. The timing creates a critical inflection point for cannabis operators navigating federal regulatory uncertainty while state-legal markets continue expanding.

The competing approaches represent fundamentally different pathways for the industry's federal future. Full legalization would eliminate Schedule I classification entirely, opening interstate commerce and traditional banking services that remain largely inaccessible to cannabis companies. Rescheduling to Schedule III, while beneficial for tax purposes under 280E reform, maintains federal prohibition and interstate commerce restrictions that limit operational efficiency for multi-state operators.

Cannabis companies face immediate strategic decisions around expansion timing and capital allocation as these policy trajectories diverge. Multi-state operators like Curaleaf (CURLF), Trulieve (TCNNF), and Green Thumb Industries (GTBIF) have built state-by-state infrastructure designed around current federal constraints. Full legalization could accelerate consolidation as interstate commerce becomes viable, while rescheduling maintains existing market fragmentation that benefits established regional players.

The legislative dynamics favor incremental progress over comprehensive reform in the near term. Rescheduling through administrative action requires fewer political hurdles than congressional legislation, particularly with Republican control of key committees. Cannabis operators are pricing in modest regulatory relief rather than transformative policy changes, reflected in sector valuations that remain compressed compared to other consumer goods industries.

Investor positioning reflects this regulatory bifurcation, with institutional capital increasingly focused on companies with strong state-level market positions and operational cash flow generation. The policy uncertainty reinforces the premium on profitable operations over growth-at-any-cost strategies that dominated earlier cannabis investment cycles. Companies demonstrating consistent EBITDA margins above 25% continue attracting capital while unprofitable operators face continued financing constraints regardless of which federal pathway ultimately prevails.